ClinicalTrials.gg
Active, not recruitingNCT06680921Updated Aug 11, 2026

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

A Phase 3 interventional study of SIM0270 and Everolimus (Afinitor®) in Locally Advanced or Metastatic Breast Cancer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Active, not recruiting at 57 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
242nd of 1,519
482 · median 120
Started
2024
with 221 others
Phase 3
331 of 1,928
120 open now
Primary completion
2028-08
later than 869 of 1,063 live
Registered
1,418th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 242nd largest by enrollment of the 1,519 interventional ones that give a count, is one of 222 that started in 2024, is one of 331 in phase 3, reaches primary completion later than 869 of the 1,063 other live ones, and was the 1,418th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This Phase III, randomized, open label, multicenter study will evaluate the efficacy and safety of SIM0270 combined with everolimus compared to physician's choice of treatment in subjects with ER+/HER2- locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitor.

03

Conditions studied

  • Locally Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with or cytologically confirmed ER+/- locally advanced or breast cancer
  2. Subjects must have at least one 1.1 and /or at least 1 lytic or mixed (lytic + sclerotic) bone lesion
  3. For women who are post menopausal must meet criteria as defined in the protocol.For women who are premenopausal or perimenopausal and for men: treatment with approved LHRH agonist therapy for screening period and the duration of study treatment
  4. Have disease that has demonstrated progression on or after prior treatment:

    1. subjects had received 1 to 2 endocrine therapies in the locally advanced or metastatic setting with disease recurrence/disease progression while being treated with endocrine therapy for ≥ 24 months and/or endocrine therapy in the locally advanced or metastatic setting, and derived a clinical benefit from therapy
    2. subjects had received ≤ 1 chemotherapy in the locally advanced or metastatic setting.
  5. Performance Status 0-1
  6. Adequate organ function

Exclusion criteria

exclusion criteria:

  1. Prior treatment with a oral selective estrogen receptor degrader (SERD) or other -ER-directed therapy, or any PI3K-AKI-mTOR inhibitors
  2. Treatment with any investigational therapy within 28 days prior to study treatment.Treatment with moderate/strong inhibitors or P-gP inhibitor within 14 days prior to first dose or moderate/strong CYP3A inducer within 28 days prior to first dose
  3. Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
  4. Active or symptomatic , carcinomatous meningitis, or
  5. Active cardiac disease or history of cardiac dysfunction, as defined in the protocol
  6. Pregnant or breastfeeding
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
482 participants (actual)

Study arms

  • Experimental
    Experimental group

    SIM0270 to be taken orally as a capsule in combination with Everolimus.

    Drug: SIM0270 · Drug: Everolimus (Afinitor®)

  • Active comparator
    Control group

    Investigator's choice of therapy of either: Fulvestrant alone (a solution for injection), or Everolimus in combination with exemestane, both a tablet to be taken orally.

    Drug: Everolimus (Afinitor®) · Drug: Exemestane tablets · Drug: Fulvestrant injection

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival(PFS) , as assessed by blinded independent review committee(BIRC) according to RECIST1.1

    PFS was defined as the time from the date of randomization to the first documented disease progression or death from any cause, whichever occurrs first.

    Time frame: 2 year

Secondary outcomes

  1. Progression free survival(PFS) , as assessed by investigator according to RECIST1.1

    PFS was defined as the time from the date of randomization to the first documented disease progression or death from any cause, whichever occurrs first.

    Time frame: 2 year

  2. Overall Survival (OS)

    OS is the time from the date of randomization to death from any cause.

    Time frame: 3 year

  3. The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0

    Time frame: 3 year

  4. Blood concentrations

    Blood concentrations of SIM0270 and everolimus

    Time frame: At five specified time points of the first 6 cycles (each cycle is 28 days)

  5. Objective Response Rate (ORR) by investigator

    The objective response rate is defined as the percentage of subjects with a complete response or partial response.

    Time frame: 2 year

  6. Objective Response Rate (DOR) by investigator

    The DoR is defined as the time from the date of first complete or partial response until the date of documented progression or death from any cause.

    Time frame: 2 year

  7. ORR by BIRC

    The objective response rate is defined as the percentage of subjects with a complete response or partial response.

    Time frame: 2 year

  8. DOR by BIRC

    The DoR is defined as the time from the date of first complete or partial response until the date of documented progression or death from any cause.

    Time frame: 2 year

  9. Clinical benefit rate(CBR) by investigator

    The clinical benefit rate is defined as the percentage of subjects with a complete response or partial response or stable disease for ≥24 weeks.

    Time frame: 2 year

  10. CBR by BIRC

    The clinical benefit rate is defined as the percentage of subjects with a complete response or partial response or stable disease for ≥24 weeks.

    Time frame: 2 year

  11. Time To Progression (TTP) by investigator

    TTP is defined as the time from randomization until the date of first documented progression.

    Time frame: 2 year

  12. Time To Progression (TTP) by BIRC

    TTP is defined as the time from randomization until the date of first documented progression.

    Time frame: 2 year

  13. Change from baseline in EQ-5D-5L scores

    Change from baseline in EQ-5D-5L scores

    Time frame: 2 year

  14. Change from baseline in FACT-B scores

    Change from baseline in FACT-B scores

    Time frame: 2 year

07

Study locations

57 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Aug 2028, 45 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 45 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 8, 2024
StartActual
Nov 14, 2024
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06680921
Collaborators
Nanjing Zaiming Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Nov 14, 2024
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Aug 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SIM0270

Start the discussion